

Savanna® - Respiratory Viral Panel 4 (RVP-4)

Project Status and next steps

- Dr. rer. nat. Jürgen Becker
- Scientific Marketing and Clinical Value Manager EMEA

Content: Results, status and next steps related to

- (I) Clinical Performance Studies
- (II) Cost benefit Evaluation Savanna RVP-4
- (IV) Publication plan and Next steps


(I) Completed Clinical Performance Studies - OVERVIEW

| Site | Country | Investigator | Comparator | Periode |
|---------------|---------|---------------------|--|-------------------------|
| multiple | USA | multiple | BioFire Respiratory Panel 2.1 | 2021 |
| LKH Feldkrich | Austria | Dr. Andreas Bösl | Roche Cobas SRAS CoV-2 | Apr. 2022 |
| Pievesistina | Italy | Pr. Vittorio Sambri | Seegene Allplex | July 2022 |
| | | | Abbott Alinity SARS CoV-2 | |
| | | | Hologic Aptima SARS CoV-2 TMA | |
| CHU Toulouse | France | Pr. Jaques Izopet | Hologic Influenza A, B RSV on Panther | Dec. 2022 and Jan. 2023 |
| | | | Hologic SARS CoV-2, Flu A, Flu B, RSV on Panther | |
| | | | Hologic Aptima SARS CoV-2 TMA | |
| Chur | Swisse | Dr. Riccarda Capaul | Xpert Xpress SARS CoV-2, Flu A, Flu B, RSV | Jan and Feb. 2023 |


(I) Completed Clinical Performance Studies - RESULTS

| Study | Positive % Agreement | | negative % Agreement | | Overall %-Agreement | N | | |
|----------------------|----------------------|---------------|----------------------|---------------|---------------------|------|-----|------|
| | Value | 95% CI | Value | 95% CI | | all | Pos | Neg |
| USA (5 Centers) | 99,44% | 96,43 – 99,97 | 100% | 99,34 – 100 | 99,89% | 896 | 178 | 718 |
| Feldkirch (Austria) | 93.62% | 87.87 – 96.85 | 97.98% | 94.57 – 99.35 | 96,17% | 339 | 141 | 198 |
| Pievesistina (Italy) | 93,83% | 85.55 – 97.71 | 98,29% | 93.35 – 99.70 | 96,46% | 198 | 81 | 117 |
| Toulouse (France) | 92,11% | 87,29 – 95,28 | 99,81% | 99,23 – 99,97 | 98,56% | 1251 | 203 | 1048 |
| Chur (Swiss) | 92,59% | 81.26 – 97.60 | 100% | 98.98 – 100 | 99,23% | 520 | 54 | 466 |
| All (1-5) | 94,67% | 92.59 – 96.21 | 99,69% | 99.36 – 99,85 | 98,66% | 3204 | 657 | 2547 |

(II) Cost Benefit-Evaluation Savanna RVP-4



International Journal of
*Environmental Research
and Public Health*




Article

Cost–Benefit of Real-Time Multiplex PCR Testing of SARS-CoV-2 in German Hospitals

Roland Diel ^{1,2,3,*} and Albert Nienhaus ^{3,4}

Int. J. Environ. Res. Public Health
2023, 20, 3447.
<https://doi.org/10.3390/ijerph20043447>



Manuscript statistic
- 540 views in 4 weeks

Results:

In probabilistic sensitivity analysis, implementing the Savanna® test saved, on average, €107 as compared to applying the clinical-judgement-only strategy. A revenue loss of €735 can be avoided when SARS-CoV-2 infection in patients coming unplanned to the hospital due to other acute illnesses are excluded immediately by POCT.

Conclusions:

Using highly sensitive and specific PCR-POCT in patients suspected of COVID-19 infection at German ERs may significantly reduce hospital expenditures.

ENDE